• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

    2/14/25 6:24:06 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Protara Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share (the "Shares")

    (Title of Class of Securities)


    74365U107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,612,531.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,612,531.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,612,531.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 34,919,772 Shares outstanding comprised of (i) 20,629,772 Shares outstanding as of November 7, 2024 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 12, 2024), (ii) 13,690,000 Shares issued in connection with the issuer's private placement (according to the issuer's Prospectus as filed with the Securities and Exchange Commission on December 11, 2024), and (iii) 600,000 Shares issuable upon exercise of certain warrants held by affiliates of the Reporting Persons.


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,612,531.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,612,531.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,612,531.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,612,531.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,612,531.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,612,531.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,203.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,203.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,203.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,203.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,203.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,203.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,203.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,203.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,203.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    74365U107


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,627,734.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,627,734.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,627,734.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Protara Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    345 Park Avenue South 3rd Floor New York, NEW YORK, 10010
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), Citadel CEMF Investments Ltd., a Cayman Islands limited company ("CCIL"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM and CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share (the "Shares")
    (e)CUSIP No.:

    74365U107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,612,531 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 15,203 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 15,203 Shares. 4. Mr. Griffin may be deemed to beneficially own 1,627,734 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 4.6% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 4.7% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,612,531 2. Citadel Securities LLC: 15,203 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 15,203 4. Mr. Griffin: 1,627,734

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,612,531 2. Citadel Securities LLC: 15,203 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 15,203 4. Mr. Griffin: 1,627,734

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:02/14/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Get the next $TARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    1/7/2026$24.00Overweight
    Piper Sandler
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:13 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:15 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Shefferman Jesse covered exercise/tax liability with 8,732 shares, decreasing direct ownership by 0.85% to 1,021,832 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara's Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 20

    2/2/26 4:05:25 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

    NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place from February 26, 2026 to February 28, 2026 in San Francisco. The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive N

    1/22/26 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

    On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending cash runway into 2028 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of canc

    1/12/26 7:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    SEC Filings

    View All

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    2/2/26 4:30:21 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/15/25 4:15:24 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/9/25 4:16:14 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Protara Therapeutics with a new price target

    Piper Sandler initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/26 9:14:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Protara Therapeutics with a new price target

    Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    4/16/25 8:13:38 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Protara Therapeutics

    Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

    3/14/25 7:42:48 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/19/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/16/25 4:05:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    View All

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Addition to the Russell 3000® Index

    NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

    6/30/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

    NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

    6/2/25 4:04:01 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/18/24 6:01:42 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/14/24 1:00:40 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Financials

    Live finance-specific insights

    View All

    Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

    TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre

    12/3/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

    NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat

    12/1/25 4:15:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

    80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label S

    11/19/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care